September 27, 2016
2 min read
Save

Brinzolamide-brimonidine lowers IOP in POAG

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The fixed combination of brinzolamide-brimonidine significantly lowers intraocular pressure in primary open-angle glaucoma and is especially useful for patients with comorbidities, according to researchers in the European Journal of Ophthalmology.

Researchers divided 44 patients into two groups of 22 subjects. For 12 weeks, group A was treated with dorzolamide-timolol twice a day and group B received brinzolamide-brimonidine. IOP was measured twice a day, at 9 a.m. and 4 p.m.

At the end of the 12 weeks, mean morning IOP reduction was 7.0 ± 2.8 mm Hg in group A and 8.4 ± 1.9 mm Hg in group B, with a significant difference found.

Afternoon IOP reduction was 8.6 ± 2.7 mm Hg in group A and 7.9 ± 1.6 mm Hg in group B, with no significant difference found by the researchers.

“It seems that brimonidine has a powerful additive effect when compared with the brinzolamide, which complements its action and outweighs brimonidine’s lower hypotensive effect when used as a monotherapy,” the researchers wrote.

The researchers also noted that an advantage of the brinzolamide-brimonidine combination is the lack of the side effects caused by beta-blockers. – by Abigail Sutton

Disclosure: The researchers reported no financial disclosures.